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Background: Cortisol and inflammatory markers have 
been increasingly reported as abnormal at psychosis onset. 
The main aim of our study was to investigate the ability 
of these biomarkers to predict treatment response at 12 
weeks follow-up in first episode psychosis. Methods: In a 
longitudinal study, we collected saliva and blood samples 
in 68 first episode psychosis patients (and 57 controls) at 
baseline and assessed response to clinician-led antipsy-
chotic treatment after 12 weeks. Moreover, we repeated 
biological measurements in 39 patients at the same time 
we assessed the response. Saliva samples were collected 
at multiple time points during the day to measure diurnal 
cortisol levels and cortisol awakening response (CAR); 
interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, tumor 
necrosis factor-α, and interferon-γ (IFN-γ) levels were 
analyzed from serum samples. Patients were divided into 
Non-Responders (n = 38) and Responders (n = 30) accord-
ing to the Remission symptom criteria of the Schizophrenia 
Working Group Consensus. Results: At first onset, Non-
Responders had markedly lower CAR (d = 0.6, P = .03) 
and higher IL-6 and IFN-γ levels (respectively, d = 1.0, P = 
.003 and d = 0.9, P = .02) when compared with Responders. 
After 12 weeks, Non-Responders show persistent lower 
CAR (P = .01), and higher IL-6 (P = .04) and IFN-γ (P 
= .05) when compared with Responders. Comparison with 
controls show that these abnormalities are present in both 
patients groups, but are more evident in Non-Responders. 
Conclusions: Cortisol and inflammatory biomarkers at the 
onset of psychosis should be considered as possible predic-
tors of treatment response, as well as potential targets for 
the development of novel therapeutic agents.
Key words: HPA axis/cytokine/inflammation/outcome/ 
stress/schizophrenia
Introduction
Early treatment response is one of the strongest predic-
tors of long-term symptomatic and functional outcome in 
psychosis.1 Unfortunately, we do not have reliable predic-
tors of early treatment response in first episode psychosis, 
which makes it impossible to tailor psychiatric care to the 
needs of the individual patient. Biomarkers of stress and 
inflammation hold great potential as clinical predictors 
of treatment response: stress plays a recognized role in 
precipitating the onset and relapse of psychosis, and the 
cortisol stress response is already abnormal at psycho-
sis onset2–4; moreover, increased inflammation has been 
shown to predict lack of a pharmacological response 
in depressed patients.5,6 In psychosis, neuroimaging bio-
markers have been shown to predict treatment response, 
including our own work assessing cortical folding defects 
and white matter integrity in first episode psychosis,7,8 but 
neuroimaging findings may lack the immediate transla-
tional impact of a blood- or saliva-based biomarker. To 
our knowledge, no study has assessed whether (salivary) 
cortisol or serum inflammatory biomarkers predict treat-
ment response at the onset of psychosis.
First episode psychosis patients show abnormalities 
in the activation of the main biological system involved 
in the stress response, the hypothalamic-pituitary-
adrenal (HPA) axis.9–11 In particular, individuals at the 
onset of psychosis show a specific pattern of HPA axis 
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abnormalities, distinct from depression or other psychi-
atric disorders, of increased cortisol levels throughout 
the day, blunted cortisol awakening response (CAR), and 
decreased cortisol response to psychosocial stressors.12–14 
Interestingly, the blunted CAR and the reduced HPA axis 
reactivity to stress have also been associated with more 
severe symptoms and worse cognitive function in patients 
with psychosis.15,16 Furthermore, the blunted CAR is not 
normalized by antipsychotic treatment, indicating that it 
may represent a stable biological feature of psychosis.12,17
Recent work has also shown a role for inflammation in 
the pathogenesis of psychotic disorders.18–20 Individuals 
suffering with psychosis show increased cytokine levels 
in peripheral blood and cerebrospinal fluid and both at 
illness onset and in later stages of the disorder.21 We have 
also previously shown that increased inflammation and 
higher cortisol levels both contribute to smaller hippo-
campal volume at the onset of psychosis.3
Only few studies have attempted to clarify the asso-
ciation between stress or inflammatory biomarkers, and 
clinical outcome (not specifically treatment response), in 
psychosis. A previous study investigating HPA axis activ-
ity in patients with chronic schizophrenia has reported 
that persistent nonsuppression of cortisol levels follow-
ing the dexamethasone test after 4 weeks of antipsychotic 
treatment was associated with poor clinical outcome.22 
Conversely, a reduction in cortisol levels after 12 weeks of 
antipsychotic treatment was associated with an improve-
ment in psychotic symptoms at 12 weeks follow-up, in 
both chronic and first episode psychosis patients.23,24 Only 
3 studies investigated the link between inflammation and 
clinical outcomes in psychosis, and all were conducted 
in patients with chronic schizophrenia; interestingly, 
they all found that higher inflammation was associated 
with a poorer clinical outcome, as indicated by either 
less improvement or earlier relapses.23,25,26 Of note in this 
context, abnormal cortisol and inflammatory biomarkers 
have also been described in association with experiences 
of early life trauma, both in depression and in psycho-
sis12,18,27,28; moreover, early life trauma in depression is 
associated with lack of treatment response,29 although no 
such data are available in psychosis.
We conducted a naturalistic longitudinal study in 
which first episode psychosis were assessed at baseline (ie, 
as soon as possible, and not later than 3 months, after 
the first contact with psychiatric services), and then were 
followed up prospectively for their treatment response at 
12 weeks. The antipsychotic treatment was clinician-led, 
and we did not influence medication choice. We also com-
pleted a second biomarker assessment at 12 weeks. The 
aims of our study were: (1) to investigate whether cortisol 
and inflammatory biomarkers at baseline predicted treat-
ment response at the 12 weeks follow-up; (2) to assess if  
changes in these biomarkers over the first 12 weeks were 
associated with treatment response in the same patients; 
and (3) to clarify if  the putative relationships between 
these biomarkers and treatment response was partly 
influenced by previous experience of early life trauma.
Methods
Subjects Recruitment and Study Design
Sixty-eight first episode psychosis patients were recruited 
in South-East London (UK) as part of the Genetics and 
Psychosis study. The recruitment strategy was based on 
contacting inpatients and outpatients units of the South 
London and Maudsley (SLAM) NHS Foundation Trust, 
interviewing staff  and reviewing clinical notes, and 
approaching all subjects aged 18–65 who presented for the 
first time to these services for a functional psychotic ill-
ness. Patients with organic psychosis, learning disabilities 
or not fluent in English were excluded from the study.30,31 
Fifty-seven healthy controls were recruited from the 
same catchment area as the patients through advertise-
ment in local newspapers, hospitals, and job centers, as 
well as from existing volunteer databases. Controls were 
screened using the Psychosis Screening Questionnaire32 
and were excluded if  they met criteria for a present or 
past psychotic disorder.
All patients were assessed as soon as possible after 
their first contact with psychiatric services, and not later 
than 3  months from this first contact. At 12 weeks, a 
clinical follow-up was completed on all patients to estab-
lish response, and a subset of 39 patients also repeated 
the biomarker measurements. Not all the 39 subjects 
completed both cortisol and cytokine assessments; in 
particular, of these 39 subjects, 24 repeated the cortisol 
assessment and 33 had serum collected and cytokines 
analyzed. The study was approved by the local Research 
Ethics Committee, in accordance with the code of ethics 
of the World Medical Association, and written informed 
consent was obtained from all participants.
Clinical Assessment and Treatment Response
At the time of the first assessment, 7 patients were drug 
naive, 33 were taking olanzapine, 16 were taking ris-
peridone, 4 were taking quetiapine, and 8 were taking 
aripiprazole. Thirty-seven patients received a DSM-IV 
diagnosis of schizophrenia/schizophreniform disorder, 
22 of schizoaffective or affective psychosis, 7 of psychotic 
disorder not otherwise specified, and 2 of delusional dis-
order. Validation of clinical diagnosis was obtained using 
the Operational Criteria (OPCRIT+),33 reviewing the 
case notes in the first month following first contact with 
services. All diagnoses were performed by qualified psy-
chiatrists, subject to comprehensive training and inter-
rater reliability testing (κ = 0.9). Psychotic symptoms 
were evaluated both at baseline and follow-up, using the 
Positive and Negative Syndrome Scale (PANSS).34
Response to treatment at 12 weeks was evaluated 
using information obtained from clinical records, patient 
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face-to-face interviews, and reports from informants, 
using the World Health Organization Personal and 
Psychiatric History Schedule—Follow-up, a standard-
ized instrument to record presence and severity of symp-
toms that has been successfully used in World Health 
Organization multicenter studies of the incidence and 
outcome of schizophrenia.35 As we previously reported,8 
response was operationalized as a reduction in symptom 
severity to the levels required by the remission criteria 
of the Schizophrenia Working Group Consensus.36 This 
consensus established a set of criteria that provide an 
absolute threshold in severity of symptoms that should 
be reached for clinical improvement. This approach was 
therefore preferred to symptom change cutoffs for this 
naturalistic study, since cut-off  points are often arbitrary, 
affected by variability in baseline symptom severity across 
studies, and are not understood intuitively by clinicians. 
Instead, the remission criteria proposed by the consensus 
are more suited for traditional concepts of remission in 
psychiatric disorders. For those patients who could not be 
reassessed at 12 weeks (n = 20), information on treatment 
response was obtained using the Personal and Psychiatric 
History Schedule (PPHS).35 As previously published,7,8 
for the purposes of treatment response, we considered 
the PPHS scores equivalent to the PANSS scores as fol-
lows: 0 was equivalent to PANSS scores 1, 2, and 3; 1 was 
equivalent to PANSS scores 5 and 6; and 2 was equiva-
lent to PANSS scores 7 and 8. In a series of secondary 
analyses we also used a continuous measure of treatment 
response. This was estimated as change in PANSS total 
scores from baseline to follow-up, taking into account 
baseline PANSS total score and subtracting a score of 30, 
as even individuals without any mental health problem 
could score 30 in the PANSS. Therefore, as done in previ-
ous articles,37 we used the following formula: ((baseline 
PANSS total score − 30) − (follow-up PANSS total score 
− 30)/(baseline PANSS total score − 30) × 100).
We collected information about stressful life events 
that occurred in the previous 6 months using a brief  life 
events questionnaire,38 and we measured perceived stress 
in the previous month using the Perceived Stress Scale.39 
Information about childhood trauma was also collected 
using a modified version of the Childhood Experience of 
Care and Abuse Questionnaire, as previously published.40
The sociodemographic characteristics of  the sam-
ples are shown in table  1. Using the above-mentioned 
criteria, 30 patients were classified as Responders and 
38 as Non-Responders. Non-Responders had signifi-
cantly higher scores of  PANSS negative symptoms at 
baseline when compared with Responders (P = .03, see 
table 1). The mean duration of  antipsychotic treatment 
at baseline was 35.5 ± 5.0 days for Responders and 46.3 
± 5.3 days for Non-Responders (P = .2). The cumula-
tive dose of  antipsychotic treatment received at the 
time of  baseline assessment was not statistically differ-
ent between Responders (chlorpromazine equivalents 
Table 1. Sociodemographic Characteristics and Baseline Levels of Stress Biomarkers
Responders 
(n = 30)
Non-Responders 
(n = 38)
Controls 
(n = 57) Test and Significance
Age (y) 29.4 ± 1.4 29.1 ± 1.3 26.8 ± 0.6 F = 2.2, df = 2, 122, P = .1
Gender (M/F) 18/12 28/10 36/21 χ2 = 1.7, P = .4
Ethnicity (white/others) 10/20 13/25 36/21 χ2 = 10.7, P = .005a,b
Number of recent stressful events 2.6 ± 0.4 2.1 ± 0.3 1.4 ± 0.2 F = 5.2, df = 2, 117, P = .007a,b
Perceived Stress Scale score 22.1 ± 1.4 20.4 ± 1.5 12.6 ± 0.8 F = 21.5, df = 2, 118, P < .001a,b
Childhood trauma (% with at least one trauma) 70% 84.2% 37% χ2 = 15.3, P < .001a,b
Baseline PANSS positive symptoms 14.1 ± 0.9 15.0 ± 1.1 — t = 0.6, df = 1, 65, P = .6
Baseline PANSS negative symptoms 13.7 ± 0.9 16.8 ± 1.0 — t = 2.2, df = 1, 65, P = .03
Baseline PANSS general symptoms 29.2 ± 1.3 29.4 ± 1.1 — t = 0.78, df = 1, 63, P = .9
Cortisol AUC-DAY (nmol h/l) 60.5 ± 8.0 60.9 ± 7.6 80.1 ± 6.2 F = 8.0, df = 2,79, P = .001a,b
Cortisol AUC CAR (nmol min/l) 705.7 ± 72.7 506.8 ± 63.0 910.4 ± 55.3 F = 13.6, df = 2, 77, P < .001a,b,c
IL1β (pg/ml) 1.8 ± 0.4 3.0 ± 0.8 2.5 ± 0.4 F = 0.9, df = 2, 66, P = .4
IL2 (pg/ml) 3.2 ± 0.8 2.1 ± 0.5 3.3 ± 0.4 F = 0.2, df = 2, 58, P = 0.8
IL4 (pg/ml) 4.5 ± 0.5 6.0 ± 1.1 3.7 ± 0.2 F = 3.3, df = 2,60, P = .04b
IL6 (pg/ml) 2.9 ± 0.9 15.7 ± 4.0 0.9 ± 0.9 F = 19.0, df = 2,63, P < .001a,b,c
IL8 (pg/ml) 200.1 ± 45.5 171.3 ± 47.6 44.3 ± 9.6 F = 10.4, df = 2,61, P < .001a,b
IL10 (pg/ml) 1.6 ± 0.2 2.4 ± 0.5 1.3 ± 0.1 F = 3.5, df = 2,60, P = .04b
TNFα (pg/ml) 13.3 ± 2.3 16.0 ± 1.7 6.4 ± 0.5 F = 20.7, df = 2, 54, P < .001a,b
IFNγ (pg/ml) 4.2 ± 2.1 20.9 ± 6.0 1.6 ± 0.2 F = 12.1, df = 2, 62, P < .001a,b,c
Note: AUC, area under the curve; CAR, cortisol awakening response; IFN, interferon; IL, interleukin; PANSS, Positive and Negative 
Syndrome Scale; TNF, tumor necrosis factor. P values <0.05 are in bold.
Post-hoc analyses significance is reported as follow:
aP < .05 Responders vs Controls.
bP < .05 Non-Responders vs Controls.
cP < .05 Responders vs Non-Responders.
1165
Biomarkers of Treatment Response in Psychosis
8091.8 ± 1387.8) and Non-Responders (chlorpromazine 
equivalents 13 115.4 ± 2865.2, P = .2). The cumulative 
dose of  antipsychotic treatment received at the time of 
follow-up assessment was also not significantly differ-
ent between Responders (chlorpromazine equivalents 
21 422.5 ± 3493.6) and Non-Responders (chlorproma-
zine equivalents 31 345.5 ± 5233.8, P = 0.1).
Salivary Cortisol Assessment
Cortisol was measured in the saliva as CAR and daily 
profile in 65 patients and in 33 controls. Twenty-four of 
the 65 patients who completed cortisol assessments at 
baseline also completed cortisol assessment at 12 weeks 
follow-up. Subjects were instructed to collect saliva sam-
ples immediately after awakening (0 min) and 15, 30, and 
60 min after awakening, and again at 1200 h and at 2000 h; 
details of saliva collection for these subjects have been 
already reported in previous articles.12,16,41 Cortisol levels 
were analyzed using the High Sensitivity Salivary Cortisol 
ELISA KIT from Salimetrics following the recommended 
procedure. As published before,10 a small number (20%) 
of samples were also measured using “Immulite”—DPC’s 
Immunoassay analyzer (www.diagnostics.siemens.com), 
and the reliability between the 2 methods was found to be 
very high (z-scores; r = .93; P < .001).
We used 2 summary measures of HPA axis activity: the 
area under the curve (AUC) of cortisol levels during the 
day (AUC-DAY; 0 min after awakening, 12 and 20 h) and 
the AUC of CAR (0, 15, 30, and 60 min after awakening); 
both formulas for the calculation of AUC were derived 
from the trapezoid formula as described by Pruessner 
et al42, and standardized z scores were used for statistical 
analyses, as previously published.10
Cytokines Analyses
Blood samples were collected in 34 patients (at baseline) 
and 36 controls using clot activator tubes for serum anal-
ysis. All patients but one (n = 33) had serum collected 
and cytokines analyzed also at 12 weeks follow-up. The 
serum was separated, aliquoted, and stored at −70°C 
before use. Biochip array technology was used to perform 
simultaneous quantitative detection of multiple analytes 
from a single patient sample. The core technology is the 
Randox Biochip (http://www.randox.com), a solid-state 
device containing an array of discrete test regions of 
immobilized antibodies specific to different cytokines 
and growth factors. A sandwich chemiluminescent immu-
noassay was employed for the cytokine array. This cyto-
kine array measures the following cytokines and growth 
factors: interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, tumor necrosis factor- α (TNF-α), interferon-γ 
(IFN-γ), vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF), and monocyte chemo-
tactic protein-1 (MCP-1). Intra-assay precision and sen-
sitivity of the cytokine array has been shown in previous 
published articles.18 We excluded IL-1α, VEGF, EGF, 
and MCP1 from the statistical analyses, as levels of most 
of the values were below the detection limit.
Data Analyses
Data were analyzed using the Statistical Package for Social 
Sciences, Version 15.0 (SPSS Inc). Continuous variables are 
presented as mean ± standard error of the mean. Chi-square 
tests were used to compare categorical variables between 
patients and controls. One-way ANOVAs followed by least 
significant difference (LSD) post-hoc analyses were applied 
to test differences in biomarkers among Responders, Non-
Responders, and controls at baseline. Repeated measures 
ANOVAs were applied to test longitudinal within-group 
changes (Responders and Non-Responders), and group 
× time (baseline and follow-up) interaction for those bio-
markers that at baseline were significantly different between 
Responders and Non-Responders. Spearman’s correla-
tions were performed to test the association between iden-
tified biomarkers of treatment response and percentage of 
clinical improvement. Boxplots of serum cytokines levels 
were generated to identify possible outliers for each sepa-
rate cytokine; the identified outliers were removed before 
running statistical analyses. Serum cytokine levels were 
normalized for the statistical analyses through logarith-
mic transformation. Serum cytokines levels are presented 
as raw values, while the analyses were conducted using the 
logarithmic-transformed values.
Table 2. Repeated Measures Analyses of Cortisol Awakening Response (CAR), Interleukin-6 (IL-6), and Interferon-γ (IFNγ) at Baseline 
and 3-mo Follow-up in Responders and Non-Responders
Responders (n = 18) Non-Responders (n = 21)
Test and Significance for 
Main Group EffectBaseline Follow-up Baseline Follow-up
Cortisol AUC CAR (nmol min/l) 766.1 ± 147.6 589.2 ± 153.4 513.8 ± 72.6 314.9 ± 70.0 F = 7.7, df = 1, 17, P = .01
IL6 (pg/ml) 3.0 ± 1.0 16.7 ± 10.7 16.1 ± 4.2 34.6 ± 12.6 F = 4.5, df = 1, 29, P = .04
IFNγ (pg/ml) 4.4 ± 2.3 10.1 ± 2.2 17.9 ± 5.6 67.1 ± 24.6 F = 4.4, df = 1, 28, P = .05
Note: Of the n = 39 patients assessed at follow-up, n = 24 (n = 12 Responders and n = 12 Non-Responders) repeated the cortisol 
assessment and n = 33 (n = 16 Responders and n = 17 Non-Responders) had cytokines measured in the serum. AUC, area under the 
curve.
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Results
Baseline CAR and Inflammatory Biomarkers Predict 
Treatment Response in First Episode Psychosis
A one-way ANOVA, including Non-Responders (NR), 
Responders (R), and healthy controls (HC), revealed sig-
nificant differences among the 3 groups for cortisol levels 
during the day (P = .001), CAR (P < .001), IL-4 (P = 
.04), IL-6 (P < .001), IL-8 (P < .001), IL-10 (P = .04), 
TNF-α (P < .001), and IFN-γ (P < .001). In contrast, no 
significant differences were found among the 3 groups for 
IL-1β and IL-2 (see table 1).
In the post-hoc analyses, only 3 variables differed 
between Non-Responders and Responders. In particular, 
Non-Responders showed a significantly lower CAR (d 
= −0.59, P = .03), and higher IL-6 (d = 1.05, P = .003) 
and IFN-γ levels (d = 0.88, P = .015) when compared 
with Responders (see figures 1–3). Of note, both Non-
Responders and Responders had significantly lower 
CAR than healthy controls (respectively, d = −1.28, P < 
.001 and d = −0.62, P = .009), although the difference 
was greater in the Non-Responders, and the trend analy-
sis revealed a significant linear relationship between CAR 
and group (P < .001: NR < R < HC, see figure 1). There 
was no significant difference in awakening time between 
the Responders and Non-Responders (P = .7).
As per CAR, both Non-Responders and Responders 
had significantly higher IL-6 levels than healthy controls 
(respectively, d = 1.24, P < .001; d = 0.75, P = .02), and 
the difference was again greater in the Non-Responders. 
The trend analysis revealed again a significant linear rela-
tionship between IL-6 and group (P < .001: NR > R > 
HC, see figure 2). Both Non-Responders and Responders 
also had higher levels of IFN-γ than healthy controls, 
although this difference was statistically significant only 
for the Non-Responders (d = 1.06, P < .001), while it 
reached a trend level of significance in the Responders 
group (d = 0.45, P = .09). The trend analysis revealed 
again a significant linear relationship between IFN-γ and 
group (P < .001: NR > R > HC, see figure 3).
For cortisol levels during the day, IL-4, IL-8, IL-10, 
and TNF-α, the post-hoc analyses showed no differences 
between Responders and Non-Responders; however, 
IL-4 and IL-10 were significantly higher only in Non-
Responders when compared with controls, while they 
were no significantly different between Responders and 
controls. Moreover, cortisol levels during the day were 
lower, while IL-8 and TNF-α were higher, in both patients 
groups when compared with controls (see table 1).
Longitudinal Changes in Cortisol and Inflammatory 
Markers
We evaluated changes over 12 weeks in Responders and 
Non-Responders for the markers that were significantly 
different at baseline between these 2 groups (ie, CAR, 
Fig. 1. Baseline mean ± standard error of the mean of cortisol 
levels at 0, 15, 30, and 60 min after awakening in Controls, 
Responders, and Non-Responders. P value indicates the 
significance of the comparison of the area under the curve of 
cortisol awakening response at one-way ANOVA.
Fig. 2. Baseline mean ± standard error of the mean interleukin 
(IL)-6 levels in Controls, Responders, and Non-Responders. P 
value indicates the significance of the comparison with the one-
way ANOVA.
Fig. 3. Baseline mean ± standard error of the mean interferon 
(IFN)-γ levels in Controls, Responders, and Non-Responders. P 
value indicates the significance of the comparison with the one-
way ANOVA.
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IL-6 and IFN-γ), with a repeated measures analysis (see 
table 2). We found a significant group effect for the CAR 
(partial η2 = 0.31, P = .01), IL-6 (partial η2 = 0.14, P = 
.04), and IFN-γ levels (partial η2 = 0.14, P = .05), indi-
cating that Non-Responders, compared with Responders, 
maintained the lower CAR, as well as the higher IL-6 
and IFN-γ levels, across the 2 time points. There was no 
time effect on either CAR (partial η2 = 0.05, P = .4) or 
IL-6 (partial η2 = 0.02, P = .4), with no group by time 
interaction (P = .9 and P = .7, respectively), indicating no 
significant changes in CAR and IL-6 levels across the 12 
weeks in the 2 groups of patients. In contrast, there was a 
significant time effect on IFN-γ levels (partial η2 = 0.22, 
P = .009), with no group by time interaction (P = .6), 
indicating that IFN-γ levels increased with time in both 
samples of patients.
There Was no Difference Between Responders and Non-
Responders in Recent and Early Life Stressors
A one-way ANOVA between Non-Responders, 
Responders, and healthy controls revealed significant dif-
ferences among the 3 groups in number of recent stress-
ful life events (P = .007), perceived stress (P < .001), and 
experience of childhood trauma (P < .001). However, 
when looking at post-hoc analyses for the 3 stress mea-
surements, there were significant differences between the 2 
patient groups and controls, but not between Responders 
and Non-Responders (see table 1).
Exploratory Analysis of the Relationship Between 
Biomarkers of Treatment Response, and Symptom 
Severity and Clinical Improvement
Since we found that Non-Responders had more severe 
negative symptoms at baseline than Responders (see 
table 1), we explored the association between biomarkers 
of treatment response and negative symptoms at baseline. 
We did not find any significant association between base-
line negative symptoms and either CAR (rho = 0.125, P 
= .4) or IL-6 levels (rho = −0.040, P = .8). However, we 
found a positive association between negative symptoms 
and IFN-γ levels (rho = 0.492, P = .004).
When we explored the association between percentage 
of clinical improvement and biomarkers of treatment 
response, we found that clinical improvement was sig-
nificantly correlated with CAR (rho = 0.500, P = .003) 
and, at trend level, with IL-6 levels (rho = −0.300, P = 
.1), suggesting that lower CAR and higher IL-6 levels at 
baseline are associated with less improvement in clinical 
symptoms. In contrast we did not find a significant corre-
lation between clinical improvement and baseline IFN-γ 
levels (rho = −0.097, P = .6).
However, in view of the fact that baseline IFN-γ levels 
were significantly associated with baseline PANSS nega-
tive symptoms, we explored whether baseline IFN-γ levels 
were also associated with severity of negative symptoms 
at follow-up. We found a significant positive correlation 
between baseline IFN-γ levels and severity of PANSS 
negative symptoms at follow-up (rho = 0.398, P = .03).
Discussion
In this longitudinal study in first episode psychosis 
patients, we show for the first time that patients who 
subsequently do not respond to 12 weeks of treatment 
already have, at illness onset, a significant lower CAR 
and higher levels of IL-6 and IFN-γ, compared with 
patients who subsequently respond. Furthermore, differ-
ences in these biomarkers between Non-Responders and 
Responders persist over the first 12 weeks of treatment. 
Finally, comparison with controls demonstrate that these 
differences between Non-Responders and Responders 
are not qualitatively different from those present between 
patients and controls, but rather represent more severe 
biological abnormalities.
In this sample, we have found that the CAR at psy-
chosis onset, but not diurnal cortisol levels, predicts sub-
sequent treatment response. This is interesting, since we 
have found, in a previous sample partially overlapping 
with this one, that patients with first episode psychosis 
in general have a blunted CAR, together with high diur-
nal cortisol levels.12 However, the blunted CAR tends to 
remain unchanged with antipsychotic treatment, while 
the elevated diurnal cortisol levels tend to be normalized 
by antipsychotic treatment.12,17 Moreover, more blunted 
CAR (but not more elevated cortisol levels during the 
day) is associated with cognitive dysfunction in these 
patients.16 Therefore, it is possible that more blunted CAR 
is a biological “trait” marker, reflecting a more severe ill-
ness that cannot be modified by treatment. Interestingly, 
a recent study testing the effects of antiglucocorticoid 
treatment (mifepristone, RU486) on neuropsychologi-
cal performance in patients with bipolar depression has 
shown that treatment with mifepristone is associated with 
an increase in CAR and with a sustained improvement in 
spatial working memory performance in these patients.43 
Therefore, future studies should investigate the role of 
antiglucocorticoid treatments in ameliorating psychotic 
symptoms and improving cognitive function, especially 
in those patients showing a blunted CAR and thus less 
likely to respond to antipsychotic treatment. The fact that 
the CAR remains unchanged after 12 weeks of antipsy-
chotic treatment in this study also confirms the notion 
that this is a trait marker.
Our findings also show that increased levels of inflam-
matory markers, in particular IL-6 and IFN-γ, are asso-
ciated with poor treatment response in these patients. 
While increased inflammation in first episode psychosis 
has been described before,19,44 and previous studies have 
shown that higher inflammation (high levels of IL-2 and 
IL-6) is associated with a poorer clinical outcome in 
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patients with treatment-resistant and/or chronic schizo-
phrenia,23,25,26 our study is the first to show that this link 
is already present at the onset of psychosis. Furthermore, 
as per the CAR, the lack of changes over the 12 weeks 
for IL-6 indicated that this may also be a more trait-like 
marker. Of note, recent meta-analyses and reviews have 
reported mixed findings from studies testing the effects of 
adjunctive treatment with anti-inflammatory treatment 
in psychosis, with some agents, such as aspirin, showing 
some beneficial effects, and other agents, such as cele-
coxib and minocycline, showing no or limited effects.45–47 
These conflicting findings may partly be explained by dif-
ferences in length of treatment and patients’ selection,47 
but particularly striking is the fact that none of the stud-
ies were stratified for baseline inflammation. As we have 
shown in this article, some patients have higher inflam-
mation than others, and it is possible that only these are 
the patients who would truly benefit from an anti-inflam-
matory treatment. Consistent with this notion, a recent 
clinical trial with TNF-α antagonist in patients with 
treatment-resistant depression showed therapeutic effects 
only in the subsample of patients who had increased 
baseline inflammatory markers.48 Therefore, increased 
baseline inflammatory markers could be used to stratify 
patients in future trials evaluating the effectiveness of 
adjuvant anti-inflammatory treatment.
Surprisingly, we found an increase in IFN-γ levels over 
the 12 weeks in both Responders and Non-Responders, a 
finding that appears counterintuitive, since a recent meta-
analysis report that antipsychotic treatment decreases 
this particular proinflammatory cytokine in patients.49 
However, all of these studies assessed patients after a 
shorter interval (4–8 weeks), and it is possible that slightly 
longer treatment with atypical antipsychotics tends to 
induce production of cytokines through their propensity 
to generate metabolic syndrome.23
The mechanisms linking the blunted CAR and the 
increased inflammation with poor treatment response 
at the onset of psychosis could partly be explained by 
the well-known effects of cortisol and inflammation on 
monoaminergic pathways and on neuroplasticity.2,41,50 
Notably, it has been recently suggested that the CAR 
prime the brain for the expected demands of the day,51 
and that a blunted CAR predicts less neuroplasticity 
later in the afternoon, as shown by the response to rapid 
transcranial magnetic stimulation.52 Therefore, a blunted 
CAR in Non-Responders may be linked to a lower syn-
aptic plasticity and to a suboptimal brain function, which 
might ultimately account for the inability of our patients 
to respond to treatment. As regards inflammation, previ-
ous studies have reported increased dopaminergic activity 
in various brain regions in offspring of rodents exposed 
to a prenatal inflammatory challenge.53 Furthermore, 
inflammatory processes negatively impact adult neu-
rogenesis and contribute to wider neurodegenerative 
processes, through their influence on the kynurenine 
pathway and downstream production of the N-methyl-
D-aspartate receptor agonist, quinolinic acid.54 The effect 
of inflammation on neuroplasticity at the onset of psy-
chosis is further supported by our findings in first episode 
psychosis, showing an association between increased IL-6 
levels and lower levels of brain-derived neurotrophic fac-
tor, which is a crucial mediator of adult neurogenesis and 
neuroplasticity.3
Interestingly, although patients had significantly 
higher levels of stress (ie, stressful life events, perceived 
stress, and experience of childhood trauma) when com-
pared with controls, there were no significant differences 
between Responders and Non-Responders for any of 
these stress measures. Therefore, our findings suggest 
that high levels of stress in psychosis are not associated 
with poor treatment response per se; rather, they seem 
associated with the activation and reactivity of biological 
systems involved in the stress response, measured here as 
CAR and inflammatory markers, which can contribute to 
poor response or treatment resistance.
Finally, while CAR and IL-6 were also associated with 
overall clinical improvement, IFN-γ was more strongly 
associated with severity of negative symptoms both at 
baseline and at follow-up. These preliminary results sug-
gest the presence of different molecular pathways asso-
ciated with treatment response, with some inflammatory 
markers (in particular IFN-γ) being more associated to 
specific clinical profiles. However, our sample size was rel-
atively small to test this particular hypothesis and, given 
the strong clinical heterogeneity of psychosis, we cannot 
exclude that the characteristics of our specific cohort may 
have contributed to this finding. Further studies would 
need to investigate this hypothesis in a larger and more 
powered sample.
Few limitations of the study need to be acknowledged. 
Firstly, this is a naturalistic study and we could not con-
trol the type and duration of antipsychotic treatment, 
which could have influenced the levels of stress bio-
markers. However, there were no significant differences 
between Responders and Non-Responders in terms of 
duration and cumulative dose of treatment suggesting 
that antipsychotic treatment was not responsible for the 
difference in the stress biomarkers between the 2 groups. 
Secondly, most of our patients were already on antipsy-
chotic treatment for 5–6 weeks when assessed at base-
line, and therefore our findings might be more indicative 
of the very first few days/weeks of antipsychotic treat-
ment rather than the time before starting any treatment. 
However, these findings could even be more interesting 
from a translational point of view, as they could aid the 
decision of clinicians to switch quickly to another and 
more effective medication in the early stages of antipsy-
chotic treatment.
In conclusion, our findings show that blunted CAR 
and increased levels of proinflammatory cytokines pre-
dict poor treatment response at the onset of psychosis. 
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These biomarkers hold strong potential as predictors 
of clinical outcome at the onset of psychosis as well as 
optimal targets for the development of novel therapeutic 
agents.
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